Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4

Journal of Psychiatric Research

Volumn 43, Issue 4, 2009, Pages 393-400

  Eser, Daniela ^a   Leicht, Gregor ^a   Baghai, Thomas ^a   Pogarell, Oliver ^a   Schüle, Cornelius ^a   Karch, Susanne ^a   Nothdurfter, Caroline ^a   Rupprecht, Rainer ^a   Mulert, Christoph ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

5 HT; Anxiety; CCK 4; Challenge paradigm; HPA axis; Panic disorder

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; TETRAGASTRIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; EVOKED AUDITORY RESPONSE; HEART RATE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LOUDNESS; MALE; NORMAL HUMAN; PANIC; PRIORITY JOURNAL; PROVOCATION TEST; SEROTONINERGIC SYSTEM;

ACOUSTIC STIMULATION; ADRENOCORTICOTROPIC HORMONE; ADULT; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; HEART RATE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LOUDNESS PERCEPTION; MALE; PANIC; PITUITARY-ADRENAL SYSTEM; RADIOIMMUNOASSAY; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TETRAGASTRIN;

EID: 58149330792     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.04.010     Document Type: Article

References (46)

1. Abelson J.L., and Liberzon I. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Neuropsychopharmacology 21 (1999) 485-494
2. Abelson J.L., Liberzon I., Young E.A., and Khan S. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. Archives of General Psychiatry 62 (2005) 668-675
3. Ackenheil M, Stotz G, Dietz-Bauer R, Vossen A. Mini International Neuropsychiatric Interview German version 5.0.0.; 1999.
4. Akiyoshi J., Isogawa K., Tsutsumi T., Kasturagi S., Kohno K., Furuta M., et al. Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia. Biological Psychiatry 42 (1997) 151-154
5. Bradwejn J., and Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scandinavian Journal of Clinical and Laboratory Investigation Suppl. (2001) 19-27
6. Bradwejn J., Koszycki D., and Meterissian G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Canadian Journal of Psychiatry 35 (1990) 83-85
7. Bradwejn J., Koszycki D., and Bourin M. Dose ranging study of the effects of cholecystokinin in healthy volunteers. Journal of Psychiatry & Neuroscience 16 (1991) 91-95
8. Bradwejn J., Koszycki D., and Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Archives of General Psychiatry 48 (1991) 603-610
9. Bradwejn J., Koszycki D., Couetoux du T.A., Paradis M., and Bourin M. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology (Berlin) 114 (1994) 257-261
10. Bradwejn J., LeGrand J.M., Koszycki D., Bates J.H., and Bourin M. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. American Journal of Psychiatry 155 (1998) 280-282
11. Brambilla F., Bellodi L., Perna G., Garberi A., Panerai A., and Sacerdote P. Lymphocyte cholecystokinin concentrations in panic disorder. American Journal of Psychiatry 150 (1993) 1111-1113
12. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Archives of General Psychiatry 46 (1989) 511-517
13. Depot M., Caille G., Mukherjee J., Katzman M.A., Cadieux A., and Bradwejn J. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology 20 (1999) 177-187
14. Eser D., Schule C., Baghai T., Floesser A., Krebs-Brown A., Enunwa M., et al. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology (Berlin) 192 4 (2007) 479-487
15. Flint A.J., Koszycki D., Vaccarino F.J., Cadieux A., Boulenger J.P., and Bradwejn J. Effect of aging on cholecystokinin-induced panic. American Journal of Psychiatry 155 (1998) 283-285
16. Harro J., Vasar E., and Bradwejn J. CCK in animal and human research on anxiety. Trends in Pharmacological Sciences 14 (1993) 244-249
17. Hegerl U., and Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biological Psychiatry 33 (1993) 173-187
18. Hegerl U., Gallinat J., and Mrowinski D. Intensity dependence of auditory evoked dipole source activity. International Journal of Psychophysiology: Official Journal of the International Organization of Psychophysiology 17 (1994) 1-13
19. Juckel G., Hegerl U., Molnar M., Csepe V., and Karmos G. Auditory evoked potentials reflect serotonergic neuronal activity-a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 21 (1999) 710-716
20. Kennedy J.L., Bradwejn J., Koszycki D., King N., Crowe R., Vincent J., et al. Investigation of cholecystokinin system genes in panic disorder. Molecular Psychiatry 4 (1999) 284-285
21. Koszycki D., Cox B.J., and Bradwejn J. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. American Journal of Psychiatry 150 (1993) 1881-1883
22. Koszycki D., Zacharko R.M., Le Melledo J.M., Young S.N., and Bradwejn J. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biological Psychiatry 40 (1996) 648-655
23. Koszycki D., Zacharko R.M., Le Melledo J.M., and Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depression and Anxiety 8 (1998) 1-7
24. Le Melledo J.M., Bradwejn J., Koszycki D., and Bichet D. Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Archives of General Psychiatry 52 (1995) 605-606
25. Le Melledo J.M., Merani S., Koszycki D., Bellavance F., Palmour R., Gutkowska J., et al. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology 20 (1999) 81-91
26. Le Melledo J.M., Arthur H., Dalton J., Woo C., Lipton N., Bellavance F., et al. The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. Journal of Psychosomatic Research 51 (2001) 513-520
27. Lowry C.A. Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis. Journal of Neuroendocrinology 14 (2002) 911-923
28. Maron E., Tasa G., Toru I., Lang A., Vasar V., and Shlik J. Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers. World Journal of Biological Psychiatry 5 (2004) 149-154
29. Maron E., Toru I., Vasar V., and Shlik J. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. Journal of Psychopharmacology 18 (2004) 194-199
30. Moran T.H., Robinson P.H., Goldrich M.S., and McHugh P.R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Research 362 (1986) 175-179
31. Mulert C., Juckel G., Augustin H., and Hegerl U. Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clinical Neurophysiology 113 (2002) 1566-1572
32. Mulert C., Juckel G., Brunnmeier M., Karch S., Leicht G., Mergl R., et al. Prediction of treatment response in major depression: integration of concepts. Journal of Affective Disorder 98 (2007) 215-225
33. Pogarell O., Tatsch K., Juckel G., Hamann C., Mulert C., Pöpperl G., et al. Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. Neuropsychopharmacology 29 (2004) 1910-1917
34. Pogarell O., Koch W., Schaaff N., Pöpperl G., Mulert C., Juckel G., et al. ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials. European Archives of Psychiatry and Clinical Neuroscience 258 (2008) 40-47
35. Rehfeld J.F. Neuronal cholecystokinin: one or multiple transmitters?. Journal of Neurochemistry 44 (1985) 1-10
36. Rehfeld J.F., and Neilson F.C. Molecular form and regional distribution of cholecystokinin in the central and peripheral nervous system. In: Bradwejn J., and Vasar E. (Eds). Cholecystokinin and anxiety: from neuron to behaviour (1995), Springer, Austin 33-56
37. Rex A., Marsden C.A., and Fink H. Cortical 5-HT-CCK interactions and anxiety-related behaviour of guinea-pigs: a microdialysis study. Neuroscience Letters 228 (1997) 79-82
38. Shlik J., Aluoja A., Vasar V., Vasar E., Podar T., and Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. Journal of Psychiatry & Neuroscience 22 (1997) 332-340
39. Siniscalchi A., Rodi D., Cavallini S., Marino S., Beani L., and Bianchi C. Effects of cholecystokinin tetrapeptide (CCK(4)) and anxiolytic drugs on the electrically evoked [(3)H]5-hydroxytryptamine outflow from rat cortical slices. Brain Research 922 (2001) 104-111
40. Tõru I., Shlik J., Maron E., Vasar V., and Nutt D.J. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology (Berlin) 186 (2006) 107-112
41. van Megen H.J., Westenberg H.G., den Boer J.A., and Kahn R.S. Cholecystokinin in anxiety. European Neuropsychopharmacology 6 (1996) 263-280
42. van Megen H.J., Westenberg H.G., den Boer J.A., and Kahn R.S. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. European Neuropsychopharmacology 6 (1996) 187-194
43. van Megen H.J., Westenberg H.G., den Boer J.A., Slaap B., and Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berlin) 129 (1997) 357-364
44. Zwanzger P., Baghai T.C., Schule C., Minov C., Padberg F., Moller H.J., et al. Tiagabine improves panic and agoraphobia in panic disorder patients. Journal of Clinical Psychiatry 62 (2001) 656-657
45. Zwanzger P., Eser D., Aicher S., Schule C., Baghai T.C., Padberg F., et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 28 (2003) 979-984
46. Zwanzger P., Eser D., Padberg F., Baghai T.C., Schule C., Rotzer F., et al. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depression and Anxiety 18 (2003) 140-143